Results 111 to 120 of about 106,553 (247)
Type I interferons in tuberculosis: Foe and occasionally friend [PDF]
, 2018 Tuberculosis remains one of the leading causes of mortality worldwide, and, despite its clinical significance, there are still significant gaps in our understanding of pathogenic and protective mechanisms triggered by Mycobacterium tuberculosis infection.
Mayer-Barber, K +3 more
core +1 more source
Transplant Infectious Disease, EarlyView.This study comparing 4‐month rifampin with 9‐month isoniazid for latent tuberculosis in kidney transplant candidates showed higher treatment completion rates and no transaminase elevations in the rifampin group. However, some patients experienced an increase in blood pressure while taking antihypertensive medications known to interact with rifampin ...
Jacques Simkins +13 more
wiley +1 more source
Breakthrough Tuberculosis in a Large Cohort of People Living With HIV on Preventive Treatment
Tropical Medicine &International Health, EarlyView.ABSTRACT Background Tuberculosis is a leading infectious cause of death globally and the main cause among those with HIV. TB preventive treatment (TPT) is key for preventing TB in people with HIV (PWH). Healthcare workers often worry about adverse effects of TPT regimens, including breakthrough TB–active TB during treatment.
N. Ruswa, G. Günther, M. Claassens
wiley +1 more source
Interaction of mycobacterium tuberculosis with the host cells: a focus in the molecular mechanism involved in trafficking and autophagy [PDF]
, 2018 Tuberculosis (TB) is an ancient disease remaining a serious health threat worldwide. It is caused by Mycobacterium tuberculosis (Mtb), an acid-fast bacilli, non-sporulated, slow-growing, immobile and aerobic.
Colombo, Maria Isabel +2 more
core
Infection Risk From Humans and Animals in the Anatomy Laboratory: A Scoping Review
Clinical Anatomy, Volume 39, Issue 3, Page 346-367, April 2026.ABSTRACT Whole‐body dissection is a cornerstone of anatomy education. During and following the COVID‐19 pandemic, exposure to infectious agents and other risks of dissection were highlighted. To identify potential risks, one must have the data outlining these risks in specific situations.
Margaret A. McNulty, Elizabeth R. Agosto
wiley +1 more source
Psoriatic Disease and Tuberculosis Nowadays
Clinical and Developmental Immunology, 2012 Psoriasis is a chronic, relapsing and remitting inflammatory skin and joint disease that has a prevalence of 2-3% in the world’s population, whereas of 1–2% in Europe.
Nicola Balato +5 more
doaj +1 more source
Managing latent tuberculosis infection and tuberculosis in children
Pulmonology, 2018 Tuberculosis (TB) is a major cause of childhood morbidity and mortality worldwide. The aim of this review is to describe the management of the child with TB and latent tuberculosis infection (LTBI).To develop this article, a working group reviewed ...
I. Carvalho +5 more
doaj +1 more source
Treatment of latent tuberculosis infection
Therapeutic Advances in Respiratory Disease, 2013 Treatment of latent tuberculosis (TB) infection is an important component of TB control programs in both high- and low-prevalence countries. Clinical trials of treatment of latent TB conducted over several decades have demonstrated that preventive treatment can reduce the risk of developing active TB up to 90%.
Madhavi J. Parekh, Neil W. Schluger
openaire +3 more sources
Pharmacology Research &Perspectives, Volume 14, Issue 2, April 2026.Consistent with previously demonstrated similarity of biosimilar ABP 501 (adalimumab‐atto) with adalimumab reference product, this study in healthy adults demonstrates the pharmacokinetic, safety, and immunogenicity similarity of a high‐concentration formulation (100 mg/mL) of ABP 501 with the original 50mg/mL formulation.
Vincent Chow +7 more
wiley +1 more source